• FDA takes key steps to establish Rare Disease Innovation Hub

  • How to get an EMA marketing authorisation

  • Getting an orphan drug marketing authorisation in the European Union

  • Revised Declaration of Helsinki adopted by the global medical community

  • CDER releases annual ‘Accelerating Rare Disease Cures (ARC) Program’ report for 2024

  • Why TMC is more than just a CRO

  • The role of pharmacovigilance in oncology drug trials

  • New Board members welcomed to TMC

  • The FDA’s Project Optimus Initiative ~ expediting life-saving drugs to market without compromising on safety!

  • TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team

  • TMC welcomes Simon Estcourt as new Chief Executive Officer (CEO) to spearhead next phase of development

  • TMC Pharma champions holistic approach to medical services in rare disease drug development

  • European Biopharmaceutical Review article 29 February 2024

  • Clinical Trials Arena article 29 February 2024

  • PharmaTimes article 29 February 2024

  • TMC appoints new CCO and strengthens senior team

  • LDC backs TMC’s international growth plan

  • LDC invests £18m in TMC Pharma Services

  • TMC announces successful CTA approval across four EU countries

  • TMC Participates at BIO-Europe 2023